RE: Just bought a few more8 Oct 2025 14:37
Yes indeed, every chance Genflow's cutting edge science in the Gene Therapy and Delivery of SIRT6 Centenarian panacea potential is already on the radar of Major Pharma at a time when Major Pharma is fully focused on M&A of cutting-edge Biotech. Confirmation of Efficacy and Proof of Concept on the Dog Trial, expected in the coming months will no doubt see a lucrative JV licensing deal with one or even both of the two Major Vet Pharma's who have signed confidential disclosure agreements with Genflow, and more importantly given the strong belief in its transition from Dogs to Humans, could see several Major players competing for the rest of the pipeline and Sirt6 platform. Exciting times ahead and share accumulation in progress, very likely by those who know more than us. Gl:-)
Pharmaceutical M&A Market Surges to Over USD 168 Billion in Q2 2025, Driven by Oncology and Biotech Deals
8/10/25
Introduction
The global pharmaceutical industry continues its powerful transformation through strategic mergers and acquisitions (M&A). In Q2 2025, deal-making activity reached unprecedented levels, reflecting companies' drive to expand portfolios, secure cutting-edge technologies, and mitigate revenue erosion from patent expirations. Major players are increasingly acquiring biotech innovators, AI-driven drug discovery firms, and specialized manufacturers to strengthen competitiveness in an evolving healthcare landscape.
According to Exactitude Consultancy, the global pharmaceutical M&A market recorded deal values exceeding USD 168 billion in Q2 2025, marking a 23% increase compared to Q2 2024. The surge was primarily fueled by blockbuster acquisitions in oncology, rare diseases, and cell & gene therapy segments, alongside a spike in cross-border transactions targeting emerging biotech hubs in Asia and Europe.
Pharmaceutical M&A Market Surges to Over USD 168 Billion in Q2 htTps://share.google/TxAazNgZ1Zqj5sYxx
Sign In
Follow the stocks
